Evidence map›Paper›PMID 42457321›Full record

ReviewZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026

[Multiple clinical effects of recombinant human growth hormone therapy].

Bin Zhou, Yu Yang

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bin ZhouDepartment of Endocrinology, Genetics and Metabolism, Jiangxi Provincial Children's Hospital, Nanchang 330006, China.
Yu YangDepartment of Endocrinology, Genetics and Metabolism, Jiangxi Provincial Children's Hospital, Nanchang 330006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant human growth hormone (rhGH) is the main therapeutic approach for height improvement. In recent years, with deepening research and clinical practice, accumulating evidence indicates that rhGH exerts additional clinical benefits on body composition, lipid metabolism, the skeletal system, and cognitive function. This article systematically reviews the multiple clinical effects of rhGH to provide a reference for optimizing treatment strategies and improving long-term health outcomes in patients.

Indexed as

Human Growth HormoneBody CompositionCognitionHumansLipid MetabolismRecombinant ProteinsHuman Growth HormoneRecombinant ProteinsBody compositionCognitive functionLipid metabolismRecombinant human growth hormoneSkeletal system

Identifiers

PMID42457321
PMCPMC13372546

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.